PMID- 26148068
OWN - NLM
STAT- MEDLINE
DCOM- 20160426
LR  - 20150729
IS  - 1473-6586 (Electronic)
IS  - 0963-0643 (Linking)
VI  - 25
IP  - 5
DP  - 2015 Sep
TI  - The role of rechallenge with targeted therapies in metastatic renal-cell 
      carcinoma.
PG  - 402-10
LID - 10.1097/MOU.0000000000000206 [doi]
AB  - PURPOSE OF REVIEW: To explore the accumulating evidence and feasibility of 
      rechallenge with agents targeting the vascular endothelial growth factor (VEGF) 
      and mammalian target of rapamycin (mTOR) pathways for incorporation into the 
      evolving management algorithm for metastatic renal-cell carcinoma (mRCC). RECENT 
      FINDINGS: The current standard of care after the development of resistance to 
      first-line targeted therapies in mRCC is sequential treatment with subsequent 
      lines of alternative anti-VEGF agents or mTOR inhibitors, with optimal sequencing 
      being the focus of ongoing research. Recent evidence from case study and 
      retrospective reports suggests that mRCC patients can achieve important clinical 
      benefits from rechallenge at later lines of therapy with the same targeted 
      therapy used for previous line treatment. Further, the results of REchallenge 
      with SUnitinib in MEtastatic, the first study of sunitinib rechallenge to include 
      a prospective component, reinforce the potential for prolonged survival with this 
      treatment approach for mRCC patients. SUMMARY: Rechallenge represents an 
      important and feasible therapeutic option for the future treatment of mRCC 
      patients. The results of ongoing prospective studies are expected to further 
      evaluate the benefits of rechallenge and better inform wherein this approach fits 
      in the treatment algorithm for mRCC.
FAU - Oudard, Stephane
AU  - Oudard S
AD  - aOncology Department, European Hospital Georges Pompidou bOncology Department, 
      Paris Descartes University, Paris, France.
FAU - Vano, Yann
AU  - Vano Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Urol
JT  - Current opinion in urology
JID - 9200621
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage/adverse effects
MH  - Carcinoma, Renal Cell/*drug therapy/enzymology/mortality/*secondary
MH  - Drug Administration Schedule
MH  - Drug Resistance, Neoplasm
MH  - Drug Substitution
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/enzymology/mortality/*pathology
MH  - Molecular Targeted Therapy
MH  - Protein Kinase Inhibitors/*administration & dosage/adverse effects
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2015/07/07 06:00
MHDA- 2016/04/27 06:00
CRDT- 2015/07/07 06:00
PHST- 2015/07/07 06:00 [entrez]
PHST- 2015/07/07 06:00 [pubmed]
PHST- 2016/04/27 06:00 [medline]
AID - 10.1097/MOU.0000000000000206 [doi]
PST - ppublish
SO  - Curr Opin Urol. 2015 Sep;25(5):402-10. doi: 10.1097/MOU.0000000000000206.